Emyria Ltd(EMD.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

EMD.AU Emyria Ltd

Closed 05-01 16:12:00 AEST

0.05

+0.00

+1.96%

High0.05	Low0.05	Vol169.42K
Open0.05	D1 Closing0.05	Amplitude7.84%
Mkt Cap19.06M	Tradable Cap8.38M	Total Shares366.63M
T/O8.69K	T/O Rate0.11%	Tradable Shares161.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"EMD.AU","market":"AU","secType":"STK","nameCN":"Emyria Ltd","latestPrice":0.052,"timestamp":1714543920000,"preClose":0.051,"halted":0,"volume":169424,"delay":0,"nameEN":"Emyria Ltd","floatShares":161090210,"shares":366629396,"eps":-0.038006,"marketStatus":"Closed","change":0.001,"latestTime":"05-01 16:12:00 AEST","open":0.049,"high":0.053,"low":0.049,"amount":8690,"amplitude":0.078431,"askPrice":0.053,"askSize":95724,"bidPrice":0.051,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.038006,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1714608000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.051,"openAndCloseTimeList":[[1714521600000,1714543200000]],"volumeRatio":0.683744,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/EMD.AU/tweets","defaultTab":"tweets","newsList":[{"id":"2429135643","title":"Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2429135643","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2429135643?lang=en_us&edition=fundamental","pubTime":"2024-04-23 10:42","pubTimestamp":1713840120,"startTime":"0","endTime":"0","summary":"ASX-listed and WA-based Emyria Limited  has announced its successful receipt of commitments for $2.3M in funding to expand its clinical services intended to treat medication-resistant PTSD with MDMA and similar compounds.Capital raisings of any kind aren’t typically smiled upon by shareholders, reflected in today’s -1.8% decline of the EMD share price to 5.5c in lunchtime trades.The company highlighted on Tuesday that its Chair, Greg Hutchinson, has subscribed for $0.3M. Total C-suite participation clocked in at $320,000.All in all, the company seeks to use the funds to expand its clinical services. Those clinical services are, ultimately, the product of a partnership with University of Western Australia  chemists.Those chemists have developed a range of ‘MDMA-like compounds’ for use in treating patients with PTSD who have not responded well to traditional methodologies for that condition.The emerging field of science – if you want to use the word ’emerging’ – has long been of interest","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-locks-in-2-3m-to-progress-mdma-research-with-chair-adding-0-3m-2024-04-23/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429318104","title":"BRIEF-Emyria Receives Bids Of A$2.3M To Expand Clinical Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2429318104","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2429318104?lang=en_us&edition=fundamental","pubTime":"2024-04-23 09:24","pubTimestamp":1713835494,"startTime":"0","endTime":"0","summary":"April 23 (Reuters) - Emyria Ltd   :   * EMYRIA RECEIVES BIDS OF A$2.3M TO EXPAND CLINICAL SERVICES   * PLACEMENT AT A$0.05 EACH SHAREFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428521953","title":"BRIEF-Emyria Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2428521953","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428521953?lang=en_us&edition=fundamental","pubTime":"2024-04-19 07:15","pubTimestamp":1713482101,"startTime":"0","endTime":"0","summary":"April 19 (Reuters) - Emyria Ltd   :   * SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428462509","title":"A good trip? Psychedelics and the future of mental health","url":"https://stock-news.laohu8.com/highlight/detail?id=2428462509","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2428462509?lang=en_us&edition=fundamental","pubTime":"2024-04-18 13:48","pubTimestamp":1713419280,"startTime":"0","endTime":"0","summary":"When psychologist Timothy Leary advised Americans to ‘turn on, tune in, drop out’ in 1966, he was thinking of psychedelic drugs – in this case, LSD – mainly in terms of its recreational use.Now there’s an emerging body of research suggesting the true value of psychedelics might be found in treating psychiatric conditions such as post-traumatic stress disorder  and persistent depression.Moreover, a flurry of recent announcements in the pharmaceutical industry space, has pointed to the possibility of Australia leading the way when it comes to innovation here. But how efficacious might these drugs be?In January, Little Green Pharma  announced that its psychedelic-focused subsidiary Reset Mind Sciences had kicked off its own trial into the clinical use of psilocybin  to treat depression, with this being conducted through the Harry Perkins Institute and Fiona Stanley Hospital, both in Perth.Emyria managing director Mike Winlo said the twin factors of changing government perspective and phar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/a-good-trip-psychedelics-and-the-future-of-mental-health-2024-04-18/","is_publish_highlight":false,"gpt_icon":0},{"id":"2426414262","title":"Fixed Income Perspectives - Looking Ahead At Q2 2024: A Pause Before A Pivot","url":"https://stock-news.laohu8.com/highlight/detail?id=2426414262","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426414262?lang=en_us&edition=fundamental","pubTime":"2024-04-11 00:00","pubTimestamp":1712764800,"startTime":"0","endTime":"0","summary":"Owners’ equivalent rent has been noisy over 1Q, however, other leading inflation indicators suggest there’s OER improvement to come in 2Q. This is supportive of a continued downward trend in inflation","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1625101509/image_1625101509.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1625101509/image_1625101509.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4683135-fixed-income-perspectives-looking-ahead-at-q2-2024-a-pause-before-a-pivot","is_publish_highlight":false,"gpt_icon":0},{"id":"2426046441","title":"Emyria launches Empax Centre – pioneering innovation in mental health treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2426046441","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2426046441?lang=en_us&edition=fundamental","pubTime":"2024-04-10 10:13","pubTimestamp":1712715180,"startTime":"0","endTime":"0","summary":"Emyria Limited  has opened the Empax Centre, a cutting-edge facility designed to advance mental health treatments, including psychedelic-assisted therapies, with a focus on PTSD sufferers.This state-of-the-art technology hub will boost Emyria’s clinical capabilities, particularly in addressing conditions such as Post-Traumatic Stress Disorder .“The Empax Centre demonstrates Emyria’s commitment to lead the way in mental health innovation within the regulatory frameworks set by the TGA,” Emyria CEO Dr. Michael Winlo said.“Our extensive research and development efforts, particularly in MDMA-assisted therapy for PTSD, have shaped our strategic approach towards scalability and profitability – essential for the widespread adoption and success of these innovative treatments.”The primary aim of the Empax Centre is to cater to individuals struggling with resistant forms of PTSD, including frontline responders. With an estimated one million Australians affected by PTSD, and many not responding t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-launches-empax-centre-pioneering-innovation-in-mental-health-treatment-2024-04-10/","is_publish_highlight":false,"gpt_icon":0},{"id":"2424832449","title":"Emyria partners with ‘Reach Wellness’ to support PTSD patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2424832449","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2424832449?lang=en_us&edition=fundamental","pubTime":"2024-04-03 11:11","pubTimestamp":1712113860,"startTime":"0","endTime":"0","summary":"Emyria Limited  Share Price | Latest News – The Market Online, a trailblazer in mental health treatment innovation, has teamed up with charity group ‘Reach Wellness’ to spearhead a pivotal study to support post-traumatic stress disorder  sufferers.The research aims to assess the effectiveness of Emyria’s MDMA-assisted therapy  program, alongside Reach Wellness’ support initiatives, for those battling PTSD.The collaboration underscores Emyria’s commitment to pioneering solutions in mental health care. Since launching community-based MDMA-assisted therapy trials in October 2023, the company’s lead psychiatrist has obtained Authorised Prescriber status, allowing Emyria to offer MDMA-assisted therapy for PTSD under stringent regulatory oversight.Under the research study agreement, Reach Wellness will launch a fundraising campaign to cover treatment and follow-up expenses for an initial group of 50 screened first responders eligible for MDMA-AT. This initiative represents a significant inve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/emyria-partners-with-reach-wellness-to-support-ptsd-patients-2024-04-03/","is_publish_highlight":false,"gpt_icon":0},{"id":"2424882446","title":"BRIEF-Emyria Enters Binding Research Study Agreement With Charity Reach Wellness","url":"https://stock-news.laohu8.com/highlight/detail?id=2424882446","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2424882446?lang=en_us&edition=fundamental","pubTime":"2024-04-03 09:17","pubTimestamp":1712107072,"startTime":"0","endTime":"0","summary":"April 3 (Reuters) - Emyria Ltd   :   * ENTERED INTO A BINDING RESEARCH STUDY AGREEMENT WITH CHARITY REACH WELLNESS   * AGREEMENT TO MANAGE OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF EMYRIA'S MDMA-ASSISTED THERAPY PROGRAM Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421291750","title":"EDF: Emerging Markets Deliver The Goods","url":"https://stock-news.laohu8.com/highlight/detail?id=2421291750","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2421291750?lang=en_us&edition=fundamental","pubTime":"2024-03-22 00:37","pubTimestamp":1711039029,"startTime":"0","endTime":"0","summary":"Emerging countries are those with developing economies that are likely to grow in the near future.Some well-known emerging countries include Brazil, Russia, China, and India, but there are many others","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/906600424/image_906600424.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/906600424/image_906600424.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4679662-edf-emerging-markets-deliver-the-goods","is_publish_highlight":false,"gpt_icon":0},{"id":"2414617399","title":"BRIEF-Emyria Posts HY Loss Attributable A$10.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2414617399","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2414617399?lang=en_us&edition=fundamental","pubTime":"2024-02-28 14:31","pubTimestamp":1709101901,"startTime":"0","endTime":"0","summary":"Feb 28 (Reuters) - Emyria Ltd   :   * HY LOSS ATTRIBUTABLE A$10.8 MILLION VERSUS LOSS A$4 MILLION   * HY REVENUE FROM ORDINARY ACTIVITIES UP 49% TO A$1.1 MILLIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402424291","title":"Stocks of the Hour: Gladiator Resources, Kali Metals, Emyria","url":"https://stock-news.laohu8.com/highlight/detail?id=2402424291","media":"Informed Investor","top":-1,"share":"https://ttm.financial/m/news/2402424291?lang=en_us&edition=fundamental","pubTime":"2024-01-10 08:43","pubTimestamp":1704847383,"startTime":"0","endTime":"0","summary":"A snapshot of the stocks on the move, featuring Gladiator Resources, Kali Metals and Emyria.","market":null,"thumbnail":"https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/ec374edb435aa1009e4be6ec00c5756d2548d197.jpg","type":0,"news_type":0,"thumbnails":["https://informed-investor.s3.ap-southeast-2.amazonaws.com/images/News/ec374edb435aa1009e4be6ec00c5756d2548d197.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.sharecafe.com.au/2024/01/10/stocks-of-the-hour-gladiator-resources-kali-metals-emyria/","is_publish_highlight":false,"gpt_icon":0},{"id":"2382228793","title":"It's Unlikely That Shareholders Will Increase Emyria Limited's (ASX:EMD) Compensation By Much This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2382228793","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2382228793?lang=en_us&edition=fundamental","pubTime":"2023-11-10 04:32","pubTimestamp":1699561971,"startTime":"0","endTime":"0","summary":"Emyria will host its Annual General Meeting on 16th of November. CEO Michael Winlo's total compensation includes salary of AU$380.0k. The overall pay is comparable to the industry average. Over the past three years, Emyria's EPS grew by 5.3%  and over the past three years, the total shareholder return was 3.3%. Performance at Emyria Limited  has been reasonably good and CEO Michael Winlo has done a decent job of steering the company in the right direction. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 16th of November. We present our case of why we think CEO compensation looks fair.Comparing Emyria Limited's CEO Compensation With The Industry. Emyria Limited has generated a total shareholder return of 3.3% over three years, so most shareholders wouldn't be too disappointed. Although, there's always room to improve. As a result, investors in the company might be reluctant about agreeing to increase CEO pay ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6BRhFnc.pgAxsBLr6Um7fw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4a502612fd94fa7765656091ba791336","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6BRhFnc.pgAxsBLr6Um7fw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4a502612fd94fa7765656091ba791336"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unlikely-shareholders-increase-emyria-limiteds-203251609.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2381487896","title":"This ASX All Ords biotech share is on a 16% tear today","url":"https://stock-news.laohu8.com/highlight/detail?id=2381487896","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2381487896?lang=en_us&edition=fundamental","pubTime":"2023-11-07 08:44","pubTimestamp":1699317875,"startTime":"0","endTime":"0","summary":"The Race Oncology Ltd  share price is catching the eye on Tuesday.In morning trade, the ASX All Ords biotech share is up 16% to $1.05.Investors have been buying the oncology focused biotechnology company's shares today following the release of a positive announcement.This relates to interim clinical results from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine  in relapsed or refractory Acute Myeloid Leukaemia  patients.Furthermore, the ASX All Ords biotech share revealed that five of the six treatment-responsive patients were able to be bridged to a stem cell transplant  within one to three months of treatment.This clinical trial of bisantrene in combination with intensive chemotherapy produced very encouraging results in younger AML patients with advanced relapsed, refractory and resistant acute myeloid leukaemia . Many of these patients achieved a complete or a partial remission, enabling a significant proportion to go on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2023/11/07/this-asx-all-ords-biotech-share-is-on-a-16-tear-today/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emeraldclinics.com.au","stockEarnings":[{"period":"1week","weight":-0.0556},{"period":"1month","weight":-0.1356},{"period":"3month","weight":0},{"period":"6month","weight":-0.2714},{"period":"1year","weight":-0.671},{"period":"ytd","weight":-0.0192}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0642},{"period":"6month","weight":0.1296},{"period":"1year","weight":0.0892},{"period":"ytd","weight":0.091}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Emerald Clinics Limited operates a network of patient-centered medical clinics that offer cannabinoid-based treatment services. It operates four medical centers in Australia. The company was incorporated in 2018 and is based in North Perth, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.110034},{"month":2,"riseRate":0.4,"avgChangeRate":0.016245},{"month":3,"riseRate":0.4,"avgChangeRate":0.000927},{"month":4,"riseRate":0,"avgChangeRate":-0.127531},{"month":5,"riseRate":0,"avgChangeRate":-0.158453},{"month":6,"riseRate":0.25,"avgChangeRate":-0.007283},{"month":7,"riseRate":0.75,"avgChangeRate":0.259447},{"month":8,"riseRate":0,"avgChangeRate":-0.073686},{"month":9,"riseRate":0.25,"avgChangeRate":-0.022214},{"month":10,"riseRate":0.5,"avgChangeRate":0.184309},{"month":11,"riseRate":0.25,"avgChangeRate":-0.074696},{"month":12,"riseRate":0.25,"avgChangeRate":0.054186}],"exchange":"ASX","name":"Emyria Ltd","nameEN":"Emyria Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emyria Ltd(EMD.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Emyria Ltd(EMD.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Emyria Ltd,EMD.AU,Emyria Ltd股票,Emyria Ltd股票老虎,Emyria Ltd股票老虎国际,Emyria Ltd行情,Emyria Ltd股票行情,Emyria Ltd股价,Emyria Ltd股市,Emyria Ltd股票价格,Emyria Ltd股票交易,Emyria Ltd股票购买,Emyria Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emyria Ltd(EMD.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Emyria Ltd(EMD.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction